Search
Fidanacogene elaparvovec
go.drugbank.com/drugs/DB16783ApprovedInvestigational[L49469,L46691] Fidanacogene elaparvovec was also approved by the FDA on April 26, 2024.[L50577] … positive results demonstrated in the open-label, single-arm Phase 3 BENEGENE-2 study, where the annualized bleeding rate (ABR) was observed to be 1.3 for the 12 months from week 12 to month 15 compared to an
Asparaginase Erwinia chrysanthemi
go.drugbank.com/drugs/DB08886ApprovedInvestigationalIt works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. … Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent.
Moxetumomab pasudotox
go.drugbank.com/drugs/DB12688ApprovedInvestigational[A38864] MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody phage-displayed. As well the residues SSY in the heavy chain are mutated to THW. … [A38864] It was developed by Astra Zeneca and FDA approved on September 13, 2018, after being granted the status of Fast Track, Priority Review and Orphan Drug designations.[L4568]
Propanoic acid
go.drugbank.com/drugs/DB03766ApprovedInvestigationalVet approvedWithdrawnIt is considered generally recognized as safe (GRAS) food ingredient by FDA, where it acts as an antimicrobial agent for food preservation and flavoring agent. … Sodium propionate is is prepared by neutralizing propionic acid with sodium hydroxide.
Avalglucosidase alfa
go.drugbank.com/drugs/DB16099ApprovedInvestigationalGAA is an essential enzyme that hydrolyzes glycogen into free glucose for use in cellular functions. … [L35160] Avalglucosidase alfa was approved by Health Canada on November 15, 2021 for the treatment of patients older than six months of age with late-onset Pompe disease.
Pravastatin
go.drugbank.com/drugs/DB00175ApprovedInvestigational[T274] This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers Squibb and FDA approved in 1991. … The manufacturing process is followed by the hydrolysis of the lactone group and the biological hydroxylation with _Streptomyces carbophilus_ to introduce the allylic 6-alcohol group.[T239]
L-Glutamine
go.drugbank.com/drugs/DB00130ApprovedInvestigationalNutraceuticalAn oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical. … It is the principal carrier of nitrogen in the body and is an important energy source for many cells.
Hepatitis A Vaccine
go.drugbank.com/drugs/DB10989ApprovedInvestigationalHepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. … against the disease caused by infection with this virus.
Products: AVAXIM 80 U PEDIATRIC, VAQTA VACCINE 25 u/0.5 mlOxogluric acid
go.drugbank.com/drugs/DB08845InvestigationalNutraceuticalOxogluric acid (α-Ketoglutarate) is not approved for any indication in the world but is an investigational drug in the United States. … In the United States a phase I clinical trial is investigating whether oxogluric acid precursors found in nutritional supplements can benefit patients with the metabolic disorder propionic acidemia.
Aluminum chloride
go.drugbank.com/drugs/DB11081ApprovedInvestigationalIn antiperspirant products, FDA approves the use of aluminum chloride as an active ingredient up to 15%, calculated on the hexahydrate form, in an aqueous solution nonaerosol dosage form [L2012]. … It may also be found in over-the-counter as an antiperspirant or prescription products as an antihemorrhagic agent.